AbbVie (ABBV)

Quick facts

Marketed products

• Abrilada · Oncology · revenue 10191
  Adalimumab-afzb binds TNF-alpha and blocks interaction with p55 and p75 cell surface receptors.
• Skyrizi · Immunology · revenue 8600
  Skyrizi works by blocking the interleukin-23 protein, which plays a key role in inflammation and immune response.
• Rinvoq · Immunology · revenue 5300
  JAK inhibitor that prevents STAT phosphorylation and activation in cytokine signaling pathways.
• Vraylar · Metabolic · revenue 3267
  Vraylar works by selectively blocking the D3 dopamine receptor, which helps regulate mood and behavior.
• Imbruvica · Oncology · revenue 3200
  Imbruvica works by blocking the activity of a specific enzyme called Bruton's tyrosine kinase (BTK), which is involved in the growth and survival of cancer cells.
• Venclexta · Oncology · revenue 2583
  Venclexta is a selective and orally bioavailable small-molecule inhibitor of BCL-2, an anti-apoptotic protein.
• Ubrelvy · Neuroscience · revenue 664
  Ubrelvy blocks the action of a molecule called calcitonin gene-related peptide, which is involved in migraine pain.
• Orilissa · Pain · revenue 600
  Orilissa blocks the hormone signals that stimulate the growth of endometrial tissue.
• Dalvance · Infectious Disease · revenue 260.0
  Dalvance works by binding to the bacterial cell wall, disrupting its synthesis and ultimately leading to cell death.
• Qulipta · Neuroscience · revenue 201
  Qulipta works by blocking the action of a natural chemical called calcitonin gene-related peptide type 1, which is involved in migraine pain.
• Campral · Neuroscience
  Campral works by modulating the activity of the GABA-A receptor, a key neurotransmitter system involved in regulating alcohol cravings and withdrawal symptoms.
• Humira · Oncology
  Adalimumab binds TNF-alpha and blocks interaction with p55 and p75 cell surface receptors.
• Lastacaft · Other
  Lastacaft blocks histamine at the H1 receptor to reduce allergic symptoms.
• Aldapsone · Metabolic
• Armour Thyroid · Endocrinology
  Armour Thyroid replaces deficient thyroid hormones by providing a combination of T4 (levothyroxine) and T3 (liothyronine) derived from desiccated porcine thyroid tissue.
• Survanta · Respiratory
• Akineton · Neuroscience
• BOTOX®/VISTABEL® · Dermatology, Neurology, Aesthetics
  BOTOX is a botulinum toxin that blocks acetylcholine release at the neuromuscular junction, causing temporary muscle paralysis.
• Bromanautine · Immunology
• Ceftaroline Fosamil · Infectious Disease
  Ceftaroline works by inhibiting bacterial cell wall synthesis through binding to penicillin-binding proteins.
• Teflaro · Infectious Disease
  Teflaro works by inhibiting bacterial cell wall synthesis, ultimately leading to bacterial cell death.
• Trilipix · Metabolic
• Nimbex · Neuroscience
  Nimbex works by blocking the action of acetylcholine at the neuromuscular junction, preventing muscle contraction.
• Nimbex · Neuroscience
  Nimbex works by blocking the action of acetylcholine at the neuromuscular junction, preventing muscle contraction.
• Celexa · Neuroscience
  Celexa works by blocking the reabsorption of serotonin in the brain, allowing more of this neurotransmitter to be available for communication between nerve cells.
• Corticosteroid (CS) · Immunology, Rheumatology, Endocrinology
  Corticosteroids suppress the immune system and reduce inflammation by binding to glucocorticoid receptors and inhibiting pro-inflammatory cytokine production.
• Enablex · Urology
  Enablex works by blocking the action of a chemical called acetylcholine on the bladder muscle, which helps to relax the muscle and improve bladder control.
• Viekira Pak (Copackaged) · Oncology
• Kybella · Other
  Kybella works by targeting and destroying excess fat cells through a process that involves disrupting the cell membrane.
• Choloxin · Metabolic
• Dicuman · Cardiovascular
• Dipivefrin · Ophthalmology
• Viberzi · Pain
  Viberzi works by activating the mu-opioid receptor in the gut to slow down bowel movements and reduce diarrhea.
• Elestat · Other
  Elestat works by binding to the histamine H1 receptor, blocking the action of histamine and reducing allergic symptoms.
• Teveten · Metabolic
• Alvinol · Neuroscience
• Fml · Immunology
• FOSCARBIDOPA · Neuroscience
  Foscarbidopa works by increasing the levels of dopamine in the brain, a neurotransmitter that is often deficient in people with Parkinson's disease.
• FOSLEVODOPA · Neuroscience
  Foslevodopa works by increasing the levels of levodopa in the brain, which helps to alleviate symptoms of Parkinson's disease.
• Mavyret · Oncology
  Mavyret works by blocking the NS3/4A protease enzyme, preventing the hepatitis C virus from replicating.

Phase 3 pipeline

• ABBV-444 · Oncology
  ABBV-444 is a selective estrogen receptor degrader (SERD) that binds to and degrades estrogen receptors, blocking estrogen-driven cancer cell growth.
• ABBV-706 · Oncology
  ABBV-706 is a selective inhibitor of colony-stimulating factor 1 receptor (CSF1R) that reduces macrophage proliferation and activation in the tumor microenvironment.
• ABBV-951 · Endocrinology/Metabolic Disease
  ABBV-951 is a long-acting GLP-1 receptor agonist designed to improve glycemic control and promote weight loss in metabolic disorders.
• ABT-450/r/ABT-267 · Virology/Hepatology
  ABT-450/r/ABT-267 is a fixed-dose combination of a hepatitis C virus NS3/4A protease inhibitor (ABT-450) boosted with ritonavir and an NS5A inhibitor (ABT-267) that blocks viral replication.
• ABT-493/ABT-530 · Virology / Hepatology
  ABT-493/ABT-530 is a fixed-dose combination of a hepatitis C virus NS3/4A protease inhibitor and an NS5A inhibitor that blocks viral replication.
• ABT-493 coformulated with ABT-530 · Virology / Hepatology
  ABT-493 is a hepatitis C virus (HCV) NS3/4A protease inhibitor that blocks viral replication, coformulated with ABT-530 (an NS5A inhibitor) to enhance antiviral activity.
• ABT-SLV187 · Cardiovascular
  ABT-SLV187 is a selective inhibitor of soluble epoxide hydrolase (sEH) that increases levels of epoxyeicosatrienoic acids (EETs) to reduce inflammation and improve cardiovascular function.
• AGN-151586 · Endocrinology / Musculoskeletal
  AGN-151586 is a selective androgen receptor modulator (SARM) that activates androgen signaling in a tissue-selective manner.
• Bimatoprost (SR) · Ophthalmology
  Bimatoprost is a prostaglandin F analog that increases uveoscleral outflow of aqueous humor to reduce intraocular pressure.
• Cariprazine Flexible Dose · Psychiatry
  Cariprazine is a dopamine D2/D3 receptor partial agonist that modulates dopaminergic and serotonergic neurotransmission to treat psychiatric disorders.
• Fumaderm · Other
• Leuprolide Acetate (LA) · Oncology
  Leuprolide acetate is a gonadotropin-releasing hormone (GnRH) agonist that suppresses luteinizing hormone and follicle-stimulating hormone, leading to decreased testosterone and estrogen production.
• Levodopa-carbidopa intestinal gel · Neurology
  Levodopa-carbidopa intestinal gel delivers dopamine precursor (levodopa) directly to the small intestine via continuous infusion, bypassing gastric degradation and improving motor symptom control in advanced Parkinson's disease.
• Levodopa/Carbidopa (LD/CD) · Neurology
  Levodopa is converted to dopamine in the brain to replace deficient neurotransmitter levels, while carbidopa inhibits premature conversion in the periphery, allowing more levodopa to reach the central nervous system.
• Matching Placebo for Upadacitinib
  This is a placebo control formulation with no active pharmaceutical ingredient, used as a comparator in clinical trials.
• Mirvetuximab soravtansine plus Bevacizumab · Oncology
  Mirvetuximab soravtansine targets folate receptor alpha on cancer cells to deliver a cytotoxic payload, while bevacizumab blocks VEGF to inhibit tumor angiogenesis.
• modified FOLFIRINOX · Oncology
  Modified FOLFIRINOX is a chemotherapy regimen that combines four drugs to target rapidly dividing cancer cells.
• OBV/PTV/r · Infectious Diseases
  Ombitasvir/paritaprevir/ritonavir is a combination of a protease inhibitor and a non-nucleoside NS5A inhibitor used to treat hepatitis C virus infection.
• ombitasvir/paritaprevir/ritonavir, dasabuvir
• Optimized antiparkinsonian treatment · Neurology
  This is a descriptive label for an optimized antiparkinsonian treatment regimen rather than a single drug entity with a defined mechanism.
• Paritaprevir/ritonavir/ombitasvir · Virology/Hepatology
  Paritaprevir inhibits hepatitis C virus NS3/4A protease, while ritonavir boosts its levels, and ombitasvir inhibits the NS5A protein, together blocking viral replication.
• Placebo for ABBV-951
  A placebo contains no active pharmaceutical ingredient and produces no direct pharmacological effect.
• Placebo for ABT-414
  Placebo is an inert substance with no active pharmacological mechanism.
• Placebo for ABT-493/ABT-530
  This is a placebo control with no active pharmacological mechanism.
• Placebo for Atogepant · Neurology
  This is a placebo control with no active pharmacological mechanism.
• Placebo for E2/NETA · Women's Health / Endocrinology
  This is a placebo control arm with no active pharmacological mechanism.
• Placebo for Elagolix
  A placebo contains no active pharmaceutical ingredient and produces no pharmacological effect.
• Placebo for Estradiol/Norethindrone Acetate · Endocrinology / Hormone Replacement Therapy
  This is a placebo control formulation containing inert ingredients with no active pharmacological effect, used as a comparator in clinical trials of Estradiol/Norethindrone Acetate.
• Placebo for Linaclotide
  This is a placebo control, containing no active pharmaceutical ingredient and therefore has no mechanistic action.
• Placebo for Navitoclax · Oncology
  Navitoclax is an inhibitor of BCL-2 family proteins.
• Placebo for Ribavirin
  A placebo contains no active pharmaceutical ingredient and produces no direct pharmacological effect.
• placebo for risankizumab IV
• Placebo for Risankizumab SC · Immunology
  This is a placebo control used in clinical trials to compare against risankizumab, an IL-23 inhibitor.
• placebo for rizankizumab
  Placebo is an inert substance with no active pharmacological mechanism.
• Placebo for Topiramate
  Placebo does not have a pharmacological effect.
• Placebo for Ubrogepant · Neurology
  A placebo contains no active pharmaceutical ingredient and produces no pharmacological effect.
• Placebo for Upadacitinib
  A placebo contains no active pharmaceutical ingredient and produces no direct pharmacological effect.
• Placebo for venetoclax
  A placebo contains no active pharmaceutical ingredient and produces no direct pharmacological effect.
• Placebo-Matching Atogepant · Neurology
  Atogepant is a calcitonin gene-related peptide (CGRP) receptor antagonist that blocks CGRP signaling to prevent migraine.
• Placebo to dupilumab · Immunology
  Dupilumab is a monoclonal antibody that blocks the action of interleukin-4 (IL-4) and interleukin-13 (IL-13), which are key cytokines involved in the inflammatory process.

Phase 2 pipeline

• ABBV-142
• ABBV-2222
• ABBV-3067
• ABBV-400
• ABBV-552 · Autoimmune diseases
  ABBV-552 is a small molecule inhibitor of the sphingosine-1-phosphate receptor 1 (S1PR1).
• ABBV-668 · Oncology
  ABBV-668 is a selective, irreversible inhibitor of Bruton's tyrosine kinase (BTK).
• ABBV-8736
• ABBV-916
• ABBV-932 · Oncology
  ABBV-932 is a bispecific antibody that simultaneously engages CD3 on T cells and a tumor-associated antigen to redirect immune cells to kill cancer cells.
• ABBV-CLS-628 · Autoimmune diseases
  ABBV-CLS-628 is a small molecule targeting the S1P1 receptor.
• ABT-414
• ABT-493 · Infectious Diseases
  ABT-493 is a protease inhibitor.
• ABT-494 · Immunology
  ABT-494 is a JAK1 inhibitor that selectively blocks Janus kinase 1 signaling to reduce inflammatory cytokine production and immune cell activation.
• ABT-530 · Immunology
  ABT-530 is a selective inhibitor of the chemokine receptor CCR2 that reduces inflammatory monocyte recruitment to sites of inflammation.
• AGN-151607 · Autoimmune diseases
  AGN-151607 is a small molecule that targets the S1P1 receptor.
• AGN-151607-DP
• Bimatoprost Sustained Release Implant · Ophthalmology
  Bimatoprost Sustained Release Implant works by releasing bimatoprost, a prostaglandin analog, to lower intraocular pressure.
• Dasabuvir mini tablet · Infectious Disease
  NS5A replication complex inhibitor
• IMGN151
• Leuprorelin Acetate Depot
• Local Steroid
• Modified FOLFIRI
• Ombitasvir mini tablet
• Paritaprevir mini tablet
• Ritonavir mini tablet
• TNB-383B

Phase 1 pipeline

• ABBV-011
• ABBV-066
• ABBV-075
• ABBV-085
• ABBV-101
• ABBV-1042
• ABBV-1354
• ABBV-141
• ABBV-154 Dose Formulation A
• ABBV-154 Dose Formulation B
• ABBV-155
• ABBV-157
• ABBV-181
• ABBV-243
• ABBV-277
• ABBV-291
• ABBV-295
• ABBV-2B04
• ABBV-319
• ABBV-321
• ABBV-324
• ABBV-368
• ABBV-428
• ABBV-438
• ABBV-453 · Oncology
  BTK inhibitor
• ABBV-47D11
• ABBV-525
• ABBV-547
• ABBV-621
• ABBV-637
• ABBV-6628
• ABBV-668 IR
• ABBV-701
• ABBV-711
• ABBV-722
• ABBV-901
• ABBV-903 Tablet Form 1
• ABBV-903 Tablet Form 2
• ABBV-927
• ABBV-969

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• AbbVie portfolio CI brief
• AbbVie pipeline updates RSS